AKT1 Inhibitors Selective Kinase Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AKT1 inhibitors are non-selective and have poor specificity, failing to effectively target the AKT1 isoform and other structurally similar kinases, which limits their efficacy in treating cancers associated with AKT signaling pathway dysfunctions.
Innovation Solution
Development of novel AKT1 inhibitory compounds with specific structures, such as those represented by Formula (I), (Ia), and (Ib), which are designed to selectively inhibit AKT1, potentially offering greater specificity and effectiveness in modulating AKT1 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current AKT1 inhibitors are used, then AKT1 activity is inhibited, but the inhibitors lack specificity and fail to selectively target AKT1 isoform
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that selectively interact with unique structural characteristics of the AKT1 isoform. The compounds contain specific functional groups and structural motifs (such as the heteroaryl-amide moiety and specific ring systems) that are optimized to bind preferentially to AKT1's ATP-binding pocket, which has distinct structural features compared to other kinases. This localized structural optimization enables selective inhibition of AKT1 while sparing other kinase isoforms.
Solution Approach 2:
The patent employs parameter changes by systematically modifying key molecular parameters of the inhibitor compounds, including substituent types, ring sizes, heteroatom positions, and stereochemical configurations. These parameter modifications are designed to optimize the balance between binding affinity for AKT1 and selectivity against other kinases. By adjusting these molecular parameters, the invention achieves compounds that maintain effective AKT1 inhibition while improving isoform specificity.
2Adaptability or versatility
If non-selective AKT1 inhibitors are used, then broad kinase inhibition is achieved, but efficacy in treating AKT-specific cancers is reduced
Solution Approach 1:
The patent applies the inversion principle by reversing the conventional approach: instead of designing broad-spectrum kinase inhibitors and hoping for AKT1 activity, the invention directly targets AKT1's unique structural features from the outset. The molecular design starts with AKT1-specific binding requirements and works backward to create selective inhibitors, rather than starting with general kinase inhibition and filtering for AKT1 activity. This inverted design strategy inherently produces compounds with both selectivity and therapeutic efficacy for AKT-driven cancers.
3Reliability
If existing AKT1 inhibitors are developed, then AKT1 inhibition is achieved, but structural similarity to other kinases limits selectivity
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments with specific roles: a heteroaryl-amide segment for ATP-competitive binding, a linker segment for optimal spacing, and a terminal segment for selectivity enhancement. This segmented design allows each portion to contribute specifically to AKT1 binding while the overall architecture differentiates the molecule from inhibitors targeting structurally similar kinases. The segmentation enables precise optimization of each region's contribution to selectivity and potency.
Data Source
AI summary
Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.